- Home
- DMAC vs SMID Comparison
DMAC vs SMID Comparison
Compare DMAC & SMID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- SMID
- Stock Information
- Founded
- DMAC 2000
- SMID 1960
- Country
- DMAC United States
- SMID United States
- Employees
- DMAC N/A
- SMID N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- SMID Building Materials
- Sector
- DMAC Health Care
- SMID Industrials
- Exchange
- DMAC Nasdaq
- SMID Nasdaq
- Market Cap
- DMAC 178.0M
- SMID 157.4M
- IPO Year
- DMAC N/A
- SMID 1995
- Fundamental
- Price
- DMAC $3.76
- SMID $34.93
- Analyst Decision
- DMAC Strong Buy
- SMID
- Analyst Count
- DMAC 2
- SMID 0
- Target Price
- DMAC $8.00
- SMID N/A
- AVG Volume (30 Days)
- DMAC 307.4K
- SMID 22.0K
- Earning Date
- DMAC 08-06-2025
- SMID 08-13-2025
- Dividend Yield
- DMAC N/A
- SMID N/A
- EPS Growth
- DMAC N/A
- SMID 866.67
- EPS
- DMAC N/A
- SMID 1.45
- Revenue
- DMAC N/A
- SMID $78,508,000.00
- Revenue This Year
- DMAC N/A
- SMID N/A
- Revenue Next Year
- DMAC N/A
- SMID N/A
- P/E Ratio
- DMAC N/A
- SMID $24.09
- Revenue Growth
- DMAC N/A
- SMID 31.77
- 52 Week Low
- DMAC $2.80
- SMID $25.03
- 52 Week High
- DMAC $6.82
- SMID $51.96
- Technical
- Relative Strength Index (RSI)
- DMAC 47.18
- SMID 67.05
- Support Level
- DMAC $3.48
- SMID $32.38
- Resistance Level
- DMAC $3.99
- SMID $32.19
- Average True Range (ATR)
- DMAC 0.32
- SMID 1.54
- MACD
- DMAC -0.00
- SMID 0.57
- Stochastic Oscillator
- DMAC 41.01
- SMID 93.93
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About SMID Smith-Midland Corporation
Smith-Midland Corp through its subsidiaries invents, develops, manufactures, markets, sells, and installs precast concrete products for primary use in the construction, highway, utilities, and farming industries. The firm's customers are general contractors and federal, state, and local transportation authorities. Its products include Slenderwall, JJhooks, Softsound, Sierra Wall and Easi set. A substantial portion of the company's business is derived from local, state, and federal building projects. The company generates revenues predominantly from the sale, leasing, licensing, shipping, and installation of precast concrete products for the construction, utility, and farming industries.